IN8bio shares are trading higher after the company presented data from its Phase 1 trial of INB-100 showing 100% of treated leukemia patients achieved durable complete remission at 1 year.
Portfolio Pulse from Benzinga Newsdesk
IN8bio shares are trading higher after the company presented data from its Phase 1 trial of INB-100 showing 100% of treated leukemia patients achieved durable complete remission at 1 year.
June 13, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio shares are trading higher following the presentation of positive data from its Phase 1 trial of INB-100, where 100% of treated leukemia patients achieved durable complete remission at 1 year.
The positive trial results are a significant milestone for IN8bio, indicating strong efficacy of INB-100 in treating leukemia. This is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100